A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Phase 1

Terminated

• Conditions: Castration-resistant Prostate Cancer; Prostate Cancer
• Interventions: Drug: SHR2554; Drug: SHR3680

• Registration Number: NCT03741712
• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Brief Summary

The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.

Detailed Description

This is a multicenter, open, non-randomized and dose-escalating and -expansion Phase I/II trial and it studies the tolerance, PK and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer. The Phase I part is a dose-escalating study including Ia (dose-escalation monotherapy) and Ib (dose-escalation combination therapy). Approximately 18-30 patients in Phase Ia will only receive one of five dose levels of orally SHR2554. Approximately 30\~48 patients in Phase Ib trial will receive SHR2554 combined with SHR3680, in which 2\~3 different dose levels of SHR2554 will be selected based on the result of the Phase Ia. Phase II part is a dose-expansion study. Primary endpoints of the study are dose-limiting tolerance (DLT), maximum-tolerated dose (MTD) and prostate specific antigen (PSA) response rate.

Study Timeline

• Status Verified: 2018-07
• Study First Submitted: 2018-10-17
• Study First Submitted QC: 2018-11-12
• Study First Posted: 2018-11-15
• Study Start: 2018-11-20
• Primary Completion: 2019-09-30
• Study Completion: 2020-12-08
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 9

Inclusion Criteria

1. Histologically or cytologically confirmed prostate cancer;
2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1;
3. Radiographic evidence of metastasis;
4. Sustained therapy of luteinizing hormone-releasing hormone analogue（LHRHA）or received bilateral orchiectomy; patients who did not receive bilateral orchiectomy are willing to receive sustained therapy of LHRHA;
5. Evidence of prostate cancer progression under the sustained therapy of LHRHA or bilateral orchiectomy;
6. Adequate hepatic, renal, heart, and hematological functions;
7. Patients have given voluntary written informed consent before performance of any study-related procedure not part of normal medical care,with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria

1. Have received any anti-tumor therapy in the past 4 weeks,including radiotherapy, chemotherapy, operation, targeted therapy, immunotherapy, and endocrinotherapy;
2. Planned to initiate any other anti-tumor therapies during the study;
3. Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;
4. Clinically significant cardiovascular diseases;
5. History of seizure or certain conditions that may predispose to seizure;
6. Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SHR2554	SHR2554	Participants will receive SHR2554 orally
SHR2554+SHR3680	SHR2554	Participants will receive SHR2554 combined with SHR3680 orally
SHR2554+SHR3680	SHR3680	Participants will receive SHR2554 combined with SHR3680 orally

Primary Outcome Measures

Name	Time	Method
DLT	Approximately 12 months	A DLT is any of the predefined set of unacceptable adverse events observed and at least possibly related to investigational agents
PSA response rate	Approximately 12 weeks	After the continuous therapy from randomisation to the end of the 12 weeks, the ratio of patients whose levels of PSA decreased more than 50%
MTD	Approximately 12 months	The first cycle DLTs will be utilized to determine the MTD and future dose escalations or de-escalations The first cycle DLTs will be utilized to determine the MTD and future dose escalations or de-escalations

Secondary Outcome Measures

Name	Time	Method
Time to PSA progression	Approximately 70 months	Time from randomisation to the first time of PSA progression according to the criteria of the Prostate Cancer Clinical Trials Working Group 3 （PCWG3)
Maximum Observed Plasma Concentration (Cmax)	Approximately 12 months	The single-dose and multiple dose PK will be calculated as data permits including Cmax
Objective response rate (ORR)	Approximately 70 months	The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
Under the Curve (AUC)	Approximately 12 months	The single dose and multiple dose PK will be calculated as data permits including Area AUC
Adverse events (AE)	Approximately 70 months	The type, frequency, severity, timing, seriousness, and relationship to study therapy

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China